Diabetic Kidney Disease

Patients suffering from Type 2 Diabetes have elevated blood sugar after meals. Like other endogenous pro-inflammatory substances, elevated blood sugar triggers a cascade of inflammatory processes which can damage different organs, including the kidneys.

Most people with Diabetic Kidney Disease do not have obvious symptoms. The patients will gradually have an increased and asymptomatic amount of protein in the urine. The disease is often diagnosed randomly during routine General Physician control.

Protein in urine is an indicator of inflammatory processes in various parts of the kidney. If the inflammation is left untreated, the kidney function deteriorates, and the patient will eventually require chronic dialysis or kidney transplant. Patients with Diabetic Kidney Disease have a higher morbidity and mortality.

The current standard treatment of Diabetic Kidney Disease is antidiabetics in addition to an antihypertensive drug. This therapeutic combination has demonstrated a significant decrease in urinary loss of protein and prolonged the time until dialysis. However, the combination of various antidiabetic and antihypertensive drugs are not a cure.

Consequently, when the diabetic inflammatory process develops further, urinary protein will increase again indicating disease progression.

Serodus’ pipeline of Diabetic Kidney Disease drugs are specifically targeting the, so far, therapeutically ignored anti-inflammatory processes – potentially extending the time to dialysis significantly.

Download SER150 Poster

Selected publications about the compounds are listed below:

DIABETIC KIDNEY DISEASE (SER150)

  • Low Dose Anti-thromboxane Reduces Urinary Albumin in Patients with Diabetic Kidney Disease. Steiness E, Brun N, Skarsfeldt T and Derwahl K-M. Poster presentation at ASN Kidney Week, San Diego, CA, US, October 23-28, 2018.
  • A Novel Surgery-induced Rat Model of Diabetic Nephropathy Displaying Progressive Albuminuria, Glomerular Hypertrophy and Glomerulosclerosis. Ostergaard MV, Johansen T, Secher T, Seebach FE, Rigbolt K, Skarsfeldt T, Vrang N, Fosgerau K and Fink LN. Poster presentation at ASN Kidney Week, San Diego, CA, US, October 23-28, 2018.
  • The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin. Fontana P, Alberts P, Sakariassen KS, Bounameaux H, Meyer JP, Santana Sorensen A. J Thromb Haemost. 2011 Oct;9(10):2109-11. http://www.ncbi.nlm.nih.gov/pubmed/21777369
  • EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin. Sakariassen KS, Femia EA, Daray FM, Podda GM, Razzari C, Pugliano M, Errasti AE, Armesto AR, Nowak W, Alberts P, Meyer JP, Sorensen AS, Cattaneo M, Rothlin RP. Thromb Res. 2012 Nov;130(5):746-52. http://www.ncbi.nlm.nih.gov/pubmed/22959706
  • Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation. Richardson A, Sakariassen KS, Meyer JP, Alberts P, Sorensen AS. Eur J Clin Pharmacol. 2013 Mar;69(3):459-65. http://www.ncbi.nlm.nih.gov/pubmed/22815050
  • Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells.Petri MH, Tellier C, Michiels C, Ellertsen I, Dogné JM, Bäck M. Biochem Biophys Res Commun. 2013 Nov 15;441(2):393-8. http://www.ncbi.nlm.nih.gov/pubmed/24161392
  • Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. Rollini F, Tello-Montoliu A, Patel R, Darlington A, Wilson RE, Franchi F, Muñiz-Lozano A, Desai B, Bender N, Sakariassen KS, Angiolillo DJ. J Thromb Thrombolysis. 2014;37(2):131-8. http://www.ncbi.nlm.nih.gov/pubmed/23943337
  • Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers. Tello-Montoliu A, Rollini F, Desai B, Pasqualino G, Patel R, Sorensen AS, Sakariassen KS, Angiolillo DJ. J Thromb Thrombolysis. 2012 Oct;34(3):297-9. http://www.ncbi.nlm.nih.gov/pubmed/22923024

DIABETIC KIDNEY DISEASE (SER140)